News

The transaction involved a number of elements, including: BioForce licensing its scientific applications technology, including its ViriChip, Chip-on-a-Tip and CellWell diagnostic and detection systems, to Aspera in exchange

Under the contract manufacturing agreement, DPT Laboratories will provide CPEX with capacity to supply Nasulin clinical materials in volumes sufficient for the remainder of Phase II trials and

Acrux will proceed to file a marketing application in Europe, under the brand name Ellavie. Acrux said that it has already received strong commercial interest for Ellavie from

The Drug Controller General of India had accorded its approval to Venus Remedies for launch of the fourth product developed by Venus Research Center, after completion of its

Viread is now also indicated for the treatment of chronic hepatitis B in adults. The drug is administered as a once-daily tablet, and works by blocking hepatitis B

In the action letter, the FDA informed the sponsor (Astellas) that it has completed its review of the Kynapid new drug application and that the application is approvable.

The FDA’s Center for Biologics Evaluation and Research released the first lots of Fluarix and FluLaval, allowing distribution to begin. GlaxoSmithKline (GSK) said that it plans to supply

ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase I trial, MM-121 becomes

The agreement will allow RFI to market products under the registered trademark AC-11 and capitalize on the scientifically validated qualities of the patented AC-11 compound. In third party